Achieve quality upgrade of traditional human diploid wild seedlings
HONG KONG SAR -
Media OutReach Newswire - 27 March 2024 -
AIM Vaccine Co., Ltd. (the "AIM Vaccine", together with its subsidiaries,
the "Group")
is pleased to announce that the Group has submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine on March 24, 2024.